Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00833625 · ClinicalTrials.gov registry record · NA
FDG-PET-CT and Biomarkers in Esophageal Cancer
A NA study of Esophageal Cancer and Gastrointestinal Disease, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT00833625: Completed NA study of Esophageal Cancer and Gastrointestinal Disease, sponsored by M.D. Anderson Cancer Center.
NCT00833625 is a NA study of Esophageal Cancer and Gastrointestinal Disease that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 31 participants, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00833625, a NA study of Esophageal Cancer and Gastrointestinal Disease, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if the results of a positron emission tomography/computed tomography (PET/CT) scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation) can predict how a patient with cancer of the esophagus will respond to chemoradiation. Researchers also want to learn if biomarkers (substances in the body associated with cancer) found in tumor tissue can predict response to chemoradiation.
Primary Outcome
From baseline PET-CT to "early" PET-CT \[12 + 2 days after the start of chemoradiation\] Frequency and percentage of pathologic complete response (pathCR) and extreme chemoradiation resistance (exCRTR) patients tabulated. Exploratory graphics, such as box plots, used to illustrate distribution of PET/CT maximum SUV by pathCR (or exCRTR) status. A logistic regression model fit for pathCR (and separately, for exCRTR), with baseline and the change of maximum SUV between baseline and early chemoradi
Conditions Studied
Interventions
- PROCEDURE PET/CT (FDG PET/CT)
- OTHER Biomarker Testings
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2009-02 |
| Est. Completion | 2015-12 |
| Phase | NA |
What the finished NCT00833625 record still lists
NCT00833625 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 2 interventions - of which PET/CT (FDG PET/CT) is the first listed.
NCT00833625 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00833625 about?
NCT00833625 is a clinical study titled "FDG-PET-CT and Biomarkers in Esophageal Cancer". The goal of this clinical research study is to learn if the results of a positron emission tomography/computed tomography (PET/CT) scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation) can predict how a patient with cancer of the esophagus will respond to chemoradiation. R...
What is the current status of trial NCT00833625?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2009-02. Estimated completion is 2015-12.
What conditions does trial NCT00833625 study?
This clinical trial studies the following conditions: Esophageal Cancer, Gastrointestinal Disease.
What interventions are being tested in trial NCT00833625?
The interventions under investigation include: PET/CT (FDG PET/CT) (PROCEDURE), Biomarker Testings (OTHER).
Who is sponsoring clinical trial NCT00833625?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00833625 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00833625's enrollment target sits among peer trials
31 97th of 123 higher than 27 of 123 other Esophageal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
RECRUITING · NA
-
Exercise Prehabilitation for Locoregional Esophageal Cancer
RECRUITING · NA
-
Resilience and Equity in Aging, Cancer, and Health (REACH)
RECRUITING · NA
-
Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus
RECRUITING · NA
-
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
RECRUITING · NA
-
Serial MRI Scans During Radiation Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia